INO Inovio: Prakiraan wutah bathi kanggo taun ngarep

Inovio Pharmaceuticals (INO) management is restoring confidence through a focus on DNA medicine and pipeline transparency. The earnings per share forecast for the coming year reflects market expectations, with the figure holding at 80.40. Diversification via the drug delivery platform mitigates risks, although high pre-commercial R&D expenditures are temporarily limiting the business's overall margins.

Inovio Pharmaceuticals Inc (INO): Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep saka 04.07.2022 nganti 15.11.2026

Rincian metrik komprehensif lan analitis Inovio (INO)

- rega lan prakiraan konsensus rega:

Bagan rega inovio.com|INO - Target median analis

- data kapitalisasi saham perusahaan:

Kapitalisasi pasar Inovio Pharma|INO - Rega Tumbas Perusahaan

- indikator kapitalisasi buku:

Aset Bersih saben Siji Saham Inovio|INO - Kapitalisasi Akuntansi|Rasio Nilai Pasar marang Nilai Buku inovio.com|INO - Aset Perusahaan

- data utang lan likuiditas:

- data bathi resik lan rasio valuasi:

INO - Bathi sawise pajeg|Proyeksi bathi mangsa ngarep Inovio Pharmaceuticals|INO - Nilai perusahaan marang bathi resik|Pangali Forward P/E inovio.com|INO - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Inovio Pharmaceuticals Inc|INO - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Inovio|INO - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan inovio.com|INO - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Inovio Pharmaceuticals

- rincian pendapatan lan dodolan emiten:

INO - Dodolan perusahaan|Prakiraan volume dodolan Inovio Pharmaceuticals, Inc.|INO - Rega marang dodolan|Multiplikator forward rega marang pendapatan Inovio Pharmaceuticals

Analisis wiwitan perusahaan:INO, Inovio Pharmaceuticals, Inc.

Assessing the operational resilience of the asset requires an analysis of future cash flows. For Inovio Pharmaceuticals (INO), key drivers include defense grants and patient retention in clinical trials, despite FDA regulatory barriers. The trend in market expectations for EPS growth reflects the discounting of profits, accounting for the impact of Fed rates on future margins. The stability of this indicator confirms the business's ability to generate income amid tight monetary policy.

Pesaing Inovio Pharmaceuticals